Match!
Naim Shehadeh
Rambam Health Care Campus
EndocrinologyInsulinType 1 diabetesDiabetes mellitusMedicine
108Publications
22H-index
1,623Citations
What is this?
Publications 108
Newest
#1Afif Nakhleh (Rambam Health Care Campus)H-Index: 2
#2Naim Shehadeh (Rambam Health Care Campus)H-Index: 22
Source
#1Michal Cohen (Rambam Health Care Campus)H-Index: 4
#2Meirav Oren (Rambam Health Care Campus)
Last. Naim Shehadeh (Rambam Health Care Campus)H-Index: 22
view all 9 authors...
Source
#1Afif Nakhleh (Rambam Health Care Campus)H-Index: 2
#2Naim Shehadeh (Rambam Health Care Campus)H-Index: 22
Abstract Background and aims: Diabetes mellitus is associated with a more severe course of coronavirus disease 2019 (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes angiotensin-converting enzyme II (ACE2) receptor for host cell entry. We aimed to assess the interactions between antihyperglycemic drugs and the renin-angiotensin system (RAS) and their putative roles in COVID-19. Methods A literature search was performed using Pubmed to review the interrelations...
Source
Abstract Aims Sodium glucose co-transporter 2 (SGLT2) inhibitors are associated with increased risk of genital infections. We aimed to assess incidence and risk factors associated with genital infections among female patients with type 2 diabetes mellitus (T2DM) treated with SGLT2 inhibitors. Methods We retrieved data on adult female patients with T2DM who initiated treatment with empagliflozin or dapagliflozin during March 2015–March 2018, in a large Israeli health maintenance organization (HMO...
Source
#1Muhammad Yazid Jalaludin (UM: University of Malaya)H-Index: 11
Last. Daniel WeghuberH-Index: 1
view all 7 authors...
BackgroundThe prevalence of type 2 diabetes is increasing in youths and differs from adult-onset type 2 diabetes in its characteristics and progression. Currently, only two drugs are approved for y...
Source
#1Ruth Livny (Rambam Health Care Campus)
#2Wasim Said (Rambam Health Care Campus)H-Index: 1
Last. Michal CohenH-Index: 1
view all 11 authors...
OBJECTIVES: Reports suggest that children with type 1 diabetes (T1D) perform less than the recommended daily activity and are less active than their non-diabetic peers. We aimed to: (a) Identify barriers and sources of support for exercise performance in pediatric T1D. (b) Identify strengths and limitations in the exercise-directed education provided by our diabetes team. METHODS: Patients with T1D 5 to 20 years of age were recruited while attending a routine clinic visit. Participants completed...
Source
#1Timothy BarrettH-Index: 54
#2Muhammad Yazid Jalaludin (Peninsular Malaysia)
Last. Naim ShehadehH-Index: 22
view all 5 authors...
Type 2 diabetes (T2D) is suggested to progress faster in children and young people vs type 1 diabetes (T1D) in the same age group and T2D in adults. We reviewed the evidence base for this. A literature search was performed of PubMed-indexed publications between 2000 and 2018, for the terms "pediatric" and "T2D." Results were combined and filtered for those relating to "progression." Searches of abstract books from Latin American and Asian congresses were performed to include these populations. P...
Source
#1Yael Lebenthal (TAU: Tel Aviv University)H-Index: 12
#1Yael LebenthalH-Index: 14
Last. RachmielMariannaH-Index: 14
view all 14 authors...
Our aim was to assess the efficacy, safety, and tolerability of alpha-1 antitrypsin (AAT) as a therapeutic modality for β-cell preservation in patients with recent-onset type 1 diabetes. Seventy type 1 diabetes patients (37 males; mean age 13.1 ± 4.1years) were randomized to treatment with 22 infusions of AAT (Glassia®) (60 or 120 mg/kg) or placebo. The primary outcome was the area under the curve (AUC) of C-peptide from a 2-h mixed-meal tolerance test after 52 weeks. At week 52, C-peptide was 0...
1 CitationsSource
#1Lawrence Blonde (Ochsner Medical Center)H-Index: 37
#2Julio RosenstockH-Index: 113
Last. Vanita R. Aroda (MedStar Health)H-Index: 14
view all 10 authors...
OBJECTIVE Fixed-ratio combinations of basal insulin plus glucagon-like peptide 1 receptor agonist (GLP-1 RA) allow concomitant administration of two proven complementary injectable therapies for type 2 diabetes. This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy. RESEARCH DESIGN AND METHODS LixiLan-G, a randomized, open-label, 26-week trial, compari...
1 CitationsSource
#1Afif Nakhleh (Rambam Health Care Campus)H-Index: 2
#2Naim Shehadeh (Rambam Health Care Campus)H-Index: 22
Last. Leonard SaieghH-Index: 5
view all 3 authors...
Source
12345678910